Abstract
Phase I Study of FT516, an Off-the-Shelf iPSC-Derived NK Cell Therapy, in Combination with Rituximab in Patients with Relapsed/Refractory B-Cell Lymphoma
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have